BRPI0408131A - tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite - Google Patents

tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite

Info

Publication number
BRPI0408131A
BRPI0408131A BRPI0408131-5A BRPI0408131A BRPI0408131A BR PI0408131 A BRPI0408131 A BR PI0408131A BR PI0408131 A BRPI0408131 A BR PI0408131A BR PI0408131 A BRPI0408131 A BR PI0408131A
Authority
BR
Brazil
Prior art keywords
botulinum toxin
headache
sinus
chronicles
facial pain
Prior art date
Application number
BRPI0408131-5A
Other languages
English (en)
Inventor
Gary E Borodic
Martin Acquadro
Original Assignee
Botulinum Toxin Res Ass Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Botulinum Toxin Res Ass Inc filed Critical Botulinum Toxin Res Ass Inc
Publication of BRPI0408131A publication Critical patent/BRPI0408131A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"TRATAMENTO COM TOXINA BOTULINA DE DOR FACIAL E CEFALéIA CRÈNICAS RELACIONADAS COM SINUSITE". A presente invenção refere-se a métodos para tratamento de cefaléias evocadas pelo seio usando toxina botulina injetada ou aplicada em locais subcutâneos múltiplos sobre as divisões do nervo trigeminal em tecidos macios e dermatomas revestindo os seios afetados correspondentes implicados na etiologia da dor.
BRPI0408131-5A 2003-03-06 2004-03-08 tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite BRPI0408131A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45303703P 2003-03-06 2003-03-06
PCT/IB2004/000635 WO2004078201A1 (en) 2003-03-06 2004-03-08 Treatment of sinusitis related chronic facial pain and headache with botulinum toxin

Publications (1)

Publication Number Publication Date
BRPI0408131A true BRPI0408131A (pt) 2006-03-01

Family

ID=32962756

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408131-5A BRPI0408131A (pt) 2003-03-06 2004-03-08 tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite

Country Status (17)

Country Link
US (1) US8691769B2 (pt)
EP (1) EP1599221B1 (pt)
JP (1) JP2007528352A (pt)
KR (1) KR20050109969A (pt)
CN (1) CN1874784B (pt)
AT (1) ATE538807T1 (pt)
AU (1) AU2004216904B2 (pt)
BR (1) BRPI0408131A (pt)
CA (1) CA2518157C (pt)
CR (1) CR7975A (pt)
ES (1) ES2381091T3 (pt)
IL (1) IL170157A (pt)
MX (1) MXPA05009425A (pt)
NO (1) NO20054580L (pt)
NZ (1) NZ541779A (pt)
WO (1) WO2004078201A1 (pt)
ZA (1) ZA200506715B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1565210E (pt) * 2002-11-21 2012-04-19 Ira Sanders Neurotoxina de clostrídios para utilização no tratamento de congestão nasal
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
BRPI0408114A (pt) * 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento de calázio crÈnico e hordéolo com toxina botulinìca
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
WO2005037826A1 (en) 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
JP5233399B2 (ja) * 2008-05-13 2013-07-10 ライオン株式会社 口腔スプレー用組成物及び口腔用製剤
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CN102781467A (zh) * 2009-12-15 2012-11-14 艾拉·桑德斯 鼻和鼻窦失调的治疗
US20150231068A1 (en) 2012-03-12 2015-08-20 Miotox, Llc Treatment of Migraine Headaches with Presynaptic Neurotoxin
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
AU2015280108B2 (en) * 2014-06-23 2019-11-28 Naurex, Inc. Methods of treating or ameliorating migraine
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR20170036928A (ko) 2015-09-24 2017-04-04 울산대학교 산학협력단 IKKε 억제제를 유효성분으로 함유하는 만성 부비동염 예방 또는 치료용 약학조성물
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
WO2018216974A2 (ko) * 2017-05-24 2018-11-29 주식회사 에이티지씨 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
RU2740268C1 (ru) * 2020-08-03 2021-01-12 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ РК» Минздрава России) Способ лечения пациентов среднего возраста с хроническим болевым синдромом при дорсопатиях вертеброгенного и невертеброгенного генеза
GB202116795D0 (en) * 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940728A (en) * 1985-05-17 1990-07-10 Postley John E Treatment for sino-nasal congestion
US5034461A (en) * 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5401452A (en) * 1993-07-26 1995-03-28 Environmental Protection Polymers, Inc. Methods for encapsulating waste and products thereof
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
DE69428813T2 (de) * 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
EP0758900B1 (en) * 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US5849929A (en) * 1997-09-26 1998-12-15 Uniroyal Chemical Company, Inc. Process for the preparation of imidazoline nitroxyl
US7537773B1 (en) * 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
JP3860403B2 (ja) 2000-09-25 2006-12-20 株式会社東芝 半導体メモリ装置
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020192239A1 (en) 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20040138097A1 (en) * 2002-11-01 2004-07-15 Bahman Guyuron Method and treatment for treating and preventing pain associated with compression of a nerve
PT1565210E (pt) * 2002-11-21 2012-04-19 Ira Sanders Neurotoxina de clostrídios para utilização no tratamento de congestão nasal
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache

Also Published As

Publication number Publication date
JP2007528352A (ja) 2007-10-11
KR20050109969A (ko) 2005-11-22
IL170157A (en) 2012-12-31
WO2004078201A1 (en) 2004-09-16
ES2381091T3 (es) 2012-05-23
US8691769B2 (en) 2014-04-08
CN1874784B (zh) 2010-06-09
US20040247606A1 (en) 2004-12-09
CN1874784A (zh) 2006-12-06
ATE538807T1 (de) 2012-01-15
EP1599221B1 (en) 2011-12-28
NZ541779A (en) 2008-01-31
CA2518157C (en) 2018-09-04
CR7975A (es) 2008-09-02
NO20054580L (no) 2005-12-06
CA2518157A1 (en) 2004-09-16
NO20054580D0 (no) 2005-10-05
AU2004216904A1 (en) 2004-09-16
EP1599221A1 (en) 2005-11-30
MXPA05009425A (es) 2006-02-10
AU2004216904B2 (en) 2009-12-24
ZA200506715B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
BRPI0408131A (pt) tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite
BR0305671A (pt) Emprego de silanos em agentes cosméticos e processo para o tratamento capilar
TW200503751A (en) Methods for treating sinus headache
BRPI0519593A2 (pt) composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
BRPI0415558A (pt) tratamentos com toxina de botulina de distúrbios neurológicos e neuropsiquiátricos
ATE316976T1 (de) O-aryl glucosid sglt2 inhibitoren und verfahren
BRPI0606902A2 (pt) composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
BR0312275A (pt) Composição e método para tratamento de superfìcies ou de ar, superfìcie assim tratada e artigo de manufatura
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
BRPI0403964B8 (pt) formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
BR0310026A (pt) Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
ATE311192T1 (de) Verfahren zur behandlung von chronischen geschwüren
EA200301251A1 (ru) Способ обработки подземного пласта
BR0315314A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente com necessidade do mesmo
PL1973540T3 (pl) Zastosowanie pochodnych heterocyklicznego benzo-skondensowanego sulfamidu do leczenia bólu
SE0102147D0 (sv) New methods
MX2007008764A (es) Metodos para tratar capsulitis adhesiva.
DE69534601D1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DE60139644D1 (de) Zusammensetzungen von cholesterolsulfat und aminozuckern zur verbesserung der stratum corneum funktion
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
ATE444761T1 (de) Methoden zum behandeln von demyelinisierenden krankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.